|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| Cost of revenues | |||
| Net revenues | |||
| Cost of revenues | |||
| Gross profit | |||
| Other expenses: | |||
| Selling and marketing expenses | |||
| General and administrative expenses | |||
| Research and development expenses | |||
| Total operating expenses | |||
| Operating loss | |||
| Interest income | |||
| Interest expense | |||
| Foreign exchange (losses)/gains | |||
| Government grants | |||
| Changes in fair value of warrant | |||
| Changes in fair value of amounts due to related party | |||
| Others, net | |||
| Loss before income tax | |||
| Income tax benefit | |||
| Net loss | |||
| Accretions to preferred shares redemption value | |||
| Other comprehensive income/(loss) | |||
| Foreign currency translation adjustments, net of nil tax | |||
| Fair value changes of amounts due to related party due to own credit risk | |||
| Total other comprehensive income/(loss) | |||
| Total comprehensive loss | |||
| Accretions to preferred shares redemption value | |||
| Comprehensive loss attributable to the Cheche’s ordinary shareholders | |||
| Basic | |||
| Diluted | |||
| Share-based compensation expenses included in | |||
| Selling and marketing expenses | |||
| General and administrative expenses | |||
| Research and development expenses | |||
| Net loss attributable to the Cheche’s ordinary shareholders |
Loading...